Interstitial pneumonitis

Fumihiko Hirai; Gouji Toyokawa; Taro Ohba; Hiromoto Kitajima; Masafumi Yamaguchi; Riichiroh Maruyama; Motoharu Hamatake; Takashi Seto; Kenji Sugio; Yukito Ichinose

Interstitial pneumonitis

Fumihiko Hirai, Gouji Toyokawa, Taro Ohba, Hiromoto Kitajima, Masafumi Yamaguchi, Riichiroh Maruyama, Motoharu Hamatake, Takashi Seto, Kenji Sugio, Yukito Ichinose

Research output: Contribution to journal › Article › peer-review

Abstract

The risk management of interstitial pneumonitis in cancer chemotherapy not only involves an adverse event by an anticancer drug, but there are four steps with the incidence of interstitial pneumonitis: 1) the time before chemotherapy treatment, selection of chemotherapy regimens and patients, 2) the time chemotherapy treatment is performed, 3) the time during following-up, 4) the time when interstitial pneumonitis occurs. It is necessary to decrease the risk of interstitial pneumonitis by several steps, cooperating with an entire medical staff.

Original language	English
Pages (from-to)	1782-1784
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	38
Issue number	11
Publication status	Published - Nov 2011
Externally published	Yes

All Science Journal Classification (ASJC) codes

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{6d0c94110f084b368c045b42f6da4061,

title = "Interstitial pneumonitis",

abstract = "The risk management of interstitial pneumonitis in cancer chemotherapy not only involves an adverse event by an anticancer drug, but there are four steps with the incidence of interstitial pneumonitis: 1) the time before chemotherapy treatment, selection of chemotherapy regimens and patients, 2) the time chemotherapy treatment is performed, 3) the time during following-up, 4) the time when interstitial pneumonitis occurs. It is necessary to decrease the risk of interstitial pneumonitis by several steps, cooperating with an entire medical staff.",

author = "Fumihiko Hirai and Gouji Toyokawa and Taro Ohba and Hiromoto Kitajima and Masafumi Yamaguchi and Riichiroh Maruyama and Motoharu Hamatake and Takashi Seto and Kenji Sugio and Yukito Ichinose",

year = "2011",

month = nov,

language = "English",

volume = "38",

pages = "1782--1784",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "11",

}

TY - JOUR

T1 - Interstitial pneumonitis

AU - Hirai, Fumihiko

AU - Toyokawa, Gouji

AU - Ohba, Taro

AU - Kitajima, Hiromoto

AU - Yamaguchi, Masafumi

AU - Maruyama, Riichiroh

AU - Hamatake, Motoharu

AU - Seto, Takashi

AU - Sugio, Kenji

AU - Ichinose, Yukito

PY - 2011/11

Y1 - 2011/11

N2 - The risk management of interstitial pneumonitis in cancer chemotherapy not only involves an adverse event by an anticancer drug, but there are four steps with the incidence of interstitial pneumonitis: 1) the time before chemotherapy treatment, selection of chemotherapy regimens and patients, 2) the time chemotherapy treatment is performed, 3) the time during following-up, 4) the time when interstitial pneumonitis occurs. It is necessary to decrease the risk of interstitial pneumonitis by several steps, cooperating with an entire medical staff.

AB - The risk management of interstitial pneumonitis in cancer chemotherapy not only involves an adverse event by an anticancer drug, but there are four steps with the incidence of interstitial pneumonitis: 1) the time before chemotherapy treatment, selection of chemotherapy regimens and patients, 2) the time chemotherapy treatment is performed, 3) the time during following-up, 4) the time when interstitial pneumonitis occurs. It is necessary to decrease the risk of interstitial pneumonitis by several steps, cooperating with an entire medical staff.

UR - http://www.scopus.com/inward/record.url?scp=84856050229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856050229&partnerID=8YFLogxK

M3 - Article

C2 - 22083185

AN - SCOPUS:84856050229

SN - 0385-0684

VL - 38

SP - 1782

EP - 1784

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 11

ER -

Interstitial pneumonitis

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this